Birdwatch Note Rating
2024-05-08 12:08:54 UTC - HELPFUL
Rated by Participant: 6DDC8F86B3D98F717BC0004CB323E8FD723042CF179F8CFE265FB07396950D06
Participant Details
Original Note:
Misleading. AstraZeneca withdrew its vaccine due to lack of market demand: other vaccines tackle newer variants https://www.theguardian.com/business/article/2024/may/08/astrazeneca-withdraws-covid-19-vaccine-worldwide-citing-surplus-of-newer-vaccines Numerous studies quantify the rarity of TTS complications: https://www.bmj.com/content/374/bmj.n1931 https://www.cnbc.com/2021/08/12/blood-clots-linked-to-astrazeneca-shot-have-22percent-mortality-rate-study.html https://www.tga.gov.au/news/covid-19-vaccine-safety-reports/covid-19-vaccine-weekly-safety-report-27-01-2022 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3886421 https://www.hdruk.ac.uk/news/two-health-data-research-uk-studies-find-only-small-elevated-risk-of-blood-clots-following-astrazeneca-covid-19-vaccination/ TTS complications were publicized & contextualized back in Mar & Jul 2021 https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-the-safety-of-covid-19-vaccine-astrazeneca.html https://www.astrazeneca.com/media-centre/press-releases/2021/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose.html
All Note Details